**[163] RONDINX - MICROBIOME GROWTH DYNAMICS IN HEALTH AND DISEASE**

**Guy Harmelin1, 1 Rondinx**

**ABSTRACT TEMPLATE for RondinX**

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

**Investment Rational**

RondinX TMAP (Total Mictobiome Analytic Platform) is the only tool that provides both static and dynamic analysis of the bacterial strain ecosystem, enabling disease screening, diagnostics, therapy monitoring, biomarker and target discovery. RodninX is led by serial entrepreneurs Dr. Rafi Gidron and Dr. Guy Harmelin. RondinX has exclusively licensed from YEDA (the commercial arm of the Weizmann Institute) intellectual property created by Prof. Eran Segal from the Department of Computational Biology of and Dr. Eran Elinav from the Department of Immunology at Weizmann Institute of Science. RondinX is currently leading an evaluation pilot with a large US based biotechnology company, and raised seed financing from a leading US based VC.

**Business Strategy**

RondinX will apply its core technology via a cloud based discovery pipeline on large metagenomic clinical cohorts in various disease spaces through joint discovery programs, aiming at identifying biomarkers and therapeutic targets in collaboration with a handful of biopharmaceutical companies. The following joint ventures will generate near-term and long-term revenues.

**Core Technology**

RondinXs’ core technology is nested in a patent pending, proprietary, cloud based, computational pipeline that leverages standard metagenomic raw sequencing data to derive insights into the dynamics of the microbiome ecosystem. The algorithmic core and associated databases are assisted by a machine-learning engine to correlate between diseases phenotype and bacterial strains dynamics within large clinical cohorts.

**Product Profile/Pipeline**

RondinX microbiome computational platform will be used to discover biomarkers and targets, on which it will develop therapeutic strategies in different disease spaces.

**What's Next?**   
RondinX has raised $ 2.5m USD from a leading US VC and will concentrate in coming year in building an refining its discovery platform while exploring collaborative discovery partnerships with leading biopharmaceutical companies and large healthcare providers in microbiome relevant disease areas.